KR101719524B1 - 이속사졸리딘 유도체 - Google Patents

이속사졸리딘 유도체 Download PDF

Info

Publication number
KR101719524B1
KR101719524B1 KR1020157006252A KR20157006252A KR101719524B1 KR 101719524 B1 KR101719524 B1 KR 101719524B1 KR 1020157006252 A KR1020157006252 A KR 1020157006252A KR 20157006252 A KR20157006252 A KR 20157006252A KR 101719524 B1 KR101719524 B1 KR 101719524B1
Authority
KR
South Korea
Prior art keywords
oxo
tetradecahydro
phenanthrene
ethyl ester
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157006252A
Other languages
English (en)
Korean (ko)
Other versions
KR20150042264A (ko
Inventor
엘레오노라 기디니
Original Assignee
키에시 파르마슈티시 엣스. 피. 에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47044778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101719524(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 키에시 파르마슈티시 엣스. 피. 에이. filed Critical 키에시 파르마슈티시 엣스. 피. 에이.
Publication of KR20150042264A publication Critical patent/KR20150042264A/ko
Application granted granted Critical
Publication of KR101719524B1 publication Critical patent/KR101719524B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0057—Nitrogen and oxygen
    • C07J71/0068—Nitrogen and oxygen at position 16(17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Otolaryngology (AREA)
KR1020157006252A 2012-09-13 2013-08-23 이속사졸리딘 유도체 Expired - Fee Related KR101719524B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12184286 2012-09-13
EP12184286.8 2012-09-13
PCT/EP2013/067509 WO2014040837A1 (en) 2012-09-13 2013-08-23 Isoxazolidine derivatives

Publications (2)

Publication Number Publication Date
KR20150042264A KR20150042264A (ko) 2015-04-20
KR101719524B1 true KR101719524B1 (ko) 2017-03-24

Family

ID=47044778

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157006252A Expired - Fee Related KR101719524B1 (ko) 2012-09-13 2013-08-23 이속사졸리딘 유도체

Country Status (28)

Country Link
US (2) US9155747B2 (enExample)
EP (1) EP2895495B1 (enExample)
JP (2) JP2015533801A (enExample)
KR (1) KR101719524B1 (enExample)
CN (2) CN108440637A (enExample)
AR (1) AR092547A1 (enExample)
AU (1) AU2013314539B2 (enExample)
BR (1) BR112015005500B1 (enExample)
CA (1) CA2884705C (enExample)
CL (1) CL2015000610A1 (enExample)
EA (1) EA027034B1 (enExample)
ES (1) ES2672140T3 (enExample)
GE (1) GEP201706708B (enExample)
HK (1) HK1209756A1 (enExample)
IL (1) IL237686A (enExample)
MA (1) MA37927B2 (enExample)
MX (1) MX364865B (enExample)
MY (1) MY182523A (enExample)
NZ (1) NZ705902A (enExample)
PE (1) PE20150675A1 (enExample)
PH (1) PH12015500534B1 (enExample)
PL (1) PL2895495T3 (enExample)
SA (1) SA515360134B1 (enExample)
SG (1) SG11201501902RA (enExample)
TN (1) TN2015000093A1 (enExample)
UA (1) UA116545C2 (enExample)
WO (1) WO2014040837A1 (enExample)
ZA (1) ZA201501691B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG193262A1 (en) 2011-03-15 2013-10-30 Chiesi Farma Spa Isoxazolidine derivatives
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3692144A1 (en) 2017-10-05 2020-08-12 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of dux4
CN115785188B (zh) * 2022-12-20 2024-06-07 湖南科益新生物医药有限公司 一种布地奈德的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012123482A2 (en) 2011-03-15 2012-09-20 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
WO2013017374A1 (en) 2011-08-01 2013-02-07 Chiesi Farmaceutici S.P.A. Anti -inflammatory steroids condensed in position 16,17 with pyrrolidine ring

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL31997A (en) * 1968-05-03 1974-03-14 Lepetit Spa Process for the preparation of pregnano(17alpha,16alpha-d)oxazolines and 16alpha,21-dihydroxy-17alpha-aminopregnanes
SE378110B (enExample) * 1972-05-19 1975-08-18 Bofors Ab
JPS617293A (ja) * 1984-06-20 1986-01-13 Mitsubishi Chem Ind Ltd 新規なコルチコイド誘導体およびその製法
US5888995A (en) * 1991-02-04 1999-03-30 Astra Aktiebolag Steroid esters
WO2003070745A2 (en) * 2002-02-20 2003-08-28 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids
WO2005028495A1 (en) * 2003-09-24 2005-03-31 Glaxo Group Limited Anti-inflammatory glucocorticoids
NO331891B1 (no) * 2007-03-20 2012-04-30 Clavis Pharma Asa Kjemiske forbindelser, et farmasoytisk preparat inneholdende slike forbindelser, samt anvendelse derav for behandling av kreft, inflammasjon og KOLS
MX2010009022A (es) * 2008-02-27 2010-09-07 Astrazeneca Ab Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
BR112012005503B1 (pt) 2009-09-11 2021-10-13 Chiesi Farmaceutici S.P.A. Derivados de isoxazolidina
TW201139369A (en) 2010-02-05 2011-11-16 Chiesi Farma Spa Pyrrolidine derivatives
BR112013022890A2 (pt) 2011-03-15 2016-09-13 Chiesi Farma Spa composto, composição farmacêutica, combinação e uso de um composto

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012123482A2 (en) 2011-03-15 2012-09-20 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
WO2013017374A1 (en) 2011-08-01 2013-02-07 Chiesi Farmaceutici S.P.A. Anti -inflammatory steroids condensed in position 16,17 with pyrrolidine ring

Also Published As

Publication number Publication date
US9155747B2 (en) 2015-10-13
EA201590390A1 (ru) 2015-08-31
HK1209756A1 (en) 2016-04-08
MA37927B2 (fr) 2021-08-31
GEP201706708B (en) 2017-07-25
BR112015005500A2 (pt) 2018-05-22
CA2884705C (en) 2021-04-13
AU2013314539B2 (en) 2018-03-08
MY182523A (en) 2021-01-25
MX2015002898A (es) 2015-06-03
PL2895495T3 (pl) 2018-10-31
KR20150042264A (ko) 2015-04-20
JP2015533801A (ja) 2015-11-26
UA116545C2 (uk) 2018-04-10
WO2014040837A1 (en) 2014-03-20
BR112015005500B1 (pt) 2022-11-22
ES2672140T3 (es) 2018-06-12
US9469669B2 (en) 2016-10-18
JP6736607B2 (ja) 2020-08-05
MX364865B (es) 2019-05-09
CN104619714A (zh) 2015-05-13
PH12015500534A1 (en) 2015-05-04
CL2015000610A1 (es) 2015-12-04
PE20150675A1 (es) 2015-05-20
PH12015500534B1 (en) 2019-01-23
EP2895495B1 (en) 2018-05-16
AU2013314539A1 (en) 2015-04-02
SA515360134B1 (ar) 2016-07-24
NZ705902A (en) 2018-04-27
MA20150350A1 (fr) 2015-10-30
CA2884705A1 (en) 2014-03-20
EP2895495A1 (en) 2015-07-22
CN108440637A (zh) 2018-08-24
SG11201501902RA (en) 2015-04-29
US20140069419A1 (en) 2014-03-13
ZA201501691B (en) 2016-10-26
JP2018162270A (ja) 2018-10-18
IL237686A (en) 2017-10-31
AR092547A1 (es) 2015-04-22
TN2015000093A1 (en) 2016-06-29
US20150376226A1 (en) 2015-12-31
EA027034B1 (ru) 2017-06-30

Similar Documents

Publication Publication Date Title
TWI494318B (zh) 異唑啶衍生物
US10280193B2 (en) Isoxazolidine derivatives
JP6736607B2 (ja) イソキサゾリジン誘導体
HK1259584A1 (en) Isoxazolidine derivatives
WO2012123493A2 (en) Isoxazolidine derivatives
HK1189599A (en) Isoxazolidine derivatives
HK1190723A (en) Isoxazolidine derivatives
HK1190723B (en) Isoxazolidine derivatives

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

FPAY Annual fee payment

Payment date: 20200311

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230321

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230321